Nanotechnology-Based Drug Delivery Systems for Melanoma Antitumoral Therapy: A Review

Melanoma (MEL) is a less common type of skin cancer, but it is more aggressive with a high mortality rate. The World Cancer Research Fund International (GLOBOCAN 2012) estimates that there were 230,000 new cases of MEL in the world in 2012. Conventional MEL treatment includes surgery and chemotherap...

Full description

Saved in:
Bibliographic Details
Published in:BioMed research international 2015-01, Vol.2015 (2015), p.1-22
Main Authors: Chorilli, Marlus, Gonçalez, M. L., Prado, Alice Haddad do, Gremião, Maria Palmira Daflon, Fujimura, Andressa Terumi, Rigon, Roberta Balansin, Oyafuso, Márcia Helena
Format: Article
Language:English
Subjects:
Antineoplastic Agents - chemistry
Antineoplastic Agents - therapeutic use
Apoptosis
Bioavailability
Cancer
Cancer therapies
Care and treatment
Cell growth
Chemotherapy
Drug Delivery Systems
Drugs
Estimates
Family medical history
Gene expression
Humans
Kinases
Medical research
Melanoma
Melanoma - drug therapy
Melanoma - pathology
Metastasis
Mortality
Nanoparticles - chemistry
Nanoparticles - therapeutic use
Nanostructure
Nanotechnology
Review
Skin cancer
Sunscreen
Therapy
Tumors
Ultraviolet radiation
Vehicles
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Melanoma (MEL) is a less common type of skin cancer, but it is more aggressive with a high mortality rate. The World Cancer Research Fund International (GLOBOCAN 2012) estimates that there were 230,000 new cases of MEL in the world in 2012. Conventional MEL treatment includes surgery and chemotherapy, but many of the chemotherapeutic agents used present undesirable properties. Drug delivery systems are an alternative strategy by which to carry antineoplastic agents. Encapsulated drugs are advantageous due to such properties as high stability, better bioavailability, controlled drug release, a long blood circulation time, selective organ or tissue distribution, a lower total required dose, and minimal toxic side effects. This review of scientific research supports applying a nanotechnology-based drug delivery system for MEL therapy.
ISSN:2314-6133
2314-6141
DOI:10.1155/2015/841817